Nasus Pharma Ltd. (NSRX)
| Market Cap | 34.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.86M |
| Shares Out | 11.71M |
| EPS (ttm) | -0.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,106 |
| Open | 3.120 |
| Previous Close | 3.180 |
| Day's Range | 2.860 - 3.200 |
| 52-Week Range | 1.980 - 9.990 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 19.67 (+575.95%) |
| Earnings Date | Mar 25, 2026 |
About NSRX
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for NSRX stock is "Strong Buy." The 12-month stock price target is $19.67, which is an increase of 575.95% from the latest price.
News
Nasus Pharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators
A proprietary powder-based intranasal platform is advancing multiple acute care therapies, led by a needle-free epinephrine product that outperforms EpiPen in speed and absorption. Phase III trials begin Q4, with NDA submission planned for mid-2027, and several pipeline products are entering the clinic this year.
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Recent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study ...
BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript
In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for th...
What's Going On With Nasus Pharma Stock On Wednesday
The Phase 2 study results indicated that NS002 has the potential to exceed EpiPen performance, demonstrating statistically significant improvements in the time to therapeutic threshold.
Nasus Pharma Transcript: Study result
Phase II results show NS002, an intranasal epinephrine powder, achieves therapeutic levels twice as fast as EpiPen, with 88% of subjects reaching threshold within 5 minutes and a favorable safety profile. The product is compact, needle-free, and may reduce the need for repeat dosing.
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4% ...
Nasus Pharma Transcript: Life Sciences Virtual Investor Forum
A proprietary powder technology enables a needle-free epinephrine product with faster absorption and superior pharmacokinetics compared to competitors. The lead product is advancing to pivotal trials, with a robust pipeline and significant market expansion potential in the growing anaphylaxis segment.
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranas...
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranas...
Nasus Pharma Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
A proprietary powder-based intranasal technology is enabling rapid, needle-free drug delivery, with the lead epinephrine product showing superior absorption and safety versus EpiPen. The company is advancing a robust pipeline, fully funded through 2027, and is well positioned for growth as the market shifts toward needle-free solutions.
Nasus Pharma to Participate in Upcoming Investor Conferences
TEL AVIV, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasa...
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranas...
Nasus Pharma Announces Closing of $15.0 Million Private Placement
TEL AVIV, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasa...
Nasus Pharma Announces Pricing of $15.0 Million Private Placement
TEL AVIV, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative i...
Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen® 91% of study participants achieved the 100 pg/ml plasma threshold at ...
Nasus Pharma CEO Issues 2025 Letter to Shareholders
TEL AVIV, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", “Nasus” or the "Company"), a clinical-stage pharmaceutical company focused on the development of inn...
Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer
Veteran CFO appointment underscores the Company's commitment to building a strong leadership team as it advances its clinical and commercial strategy Veteran CFO appointment underscores the Company's ...
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen
Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
TEL AVIV, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasa...
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
Strategic collaboration with leading global manufacturer of drug delivery systems strengthens NS002's clinical and commercial roadmap with end-to-end development support and manufacturing infrastructu...
Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference
TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd.
Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony
TEL AVIV, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative i...
Nasus Pharma Announces Closing of Initial Public Offering
TEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative i...
Nasus Pharma Announces Pricing of $10 Million Initial Public Offering
TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative i...
Israeli severe allergy biotech Nasus Pharma files and sets terms for an $11 million US IPO
Nasus Pharma, a Phase 2 biotech developing an intranasal powder for severe allergies and anaphylaxis, filed on Wednesday with the SEC to raise up to $11 million in an initial public offering.